vs
博士伦（BLCO）与科蒂（COTY）财务数据对比。点击上方公司名可切换其他公司
科蒂的季度营收约是博士伦的1.2倍（$1.7B vs $1.4B），博士伦净利率更高（-4.1% vs -7.4%，领先3.2%），博士伦同比增速更快（9.8% vs 0.5%），科蒂自由现金流更多（$513.1M vs $60.0M），过去两年博士伦的营收复合增速更高（13.1% vs 10.1%）
博士伦是知名眼健康产品企业，总部位于加拿大安大略省沃恩市，是全球规模最大的隐形眼镜、镜片护理产品、眼科药品、人工晶体及其他眼科手术产品供应商之一。品牌1853年由验光师约翰·鲍什与合伙人亨利·朗姆在美国纽约罗切斯特创立，曾是美国历史最悠久的持续运营企业之一，2013年被整体收购。
科蒂是1904年由弗朗索瓦·科蒂在巴黎创立的跨国美妆企业，现注册地为美国特拉华州，全球总部位于荷兰阿姆斯特丹。旗下业务覆盖香水、彩妆、护肤、美甲产品以及专业线和零售线护发产品的研发、生产、营销与分销，截至2024年共拥有约40个品牌。
BLCO vs COTY — 直观对比
营收规模更大
COTY
是对方的1.2倍
$1.4B
营收增速更快
BLCO
高出9.2%
0.5%
净利率更高
BLCO
高出3.2%
-7.4%
自由现金流更多
COTY
多$453.1M
$60.0M
两年增速更快
BLCO
近两年复合增速
10.1%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $1.7B |
| 净利润 | $-58.0M | $-123.6M |
| 毛利率 | — | 63.8% |
| 营业利润率 | 8.0% | 8.8% |
| 净利率 | -4.1% | -7.4% |
| 营收同比 | 9.8% | 0.5% |
| 净利润同比 | -1833.3% | -621.5% |
| 每股收益（稀释后） | $-0.16 | $-0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLCOCOTY
| Q4 25 | $1.4B | $1.7B | ||
| Q3 25 | $1.3B | $1.6B | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | $1.3B | $1.7B | ||
| Q3 24 | $1.2B | $1.7B | ||
| Q2 24 | $1.2B | $1.4B | ||
| Q1 24 | $1.1B | $1.4B |
净利润BLCOCOTY
| Q4 25 | $-58.0M | $-123.6M | ||
| Q3 25 | $-28.0M | $67.9M | ||
| Q2 25 | $-62.0M | $-68.8M | ||
| Q1 25 | $-212.0M | $-405.7M | ||
| Q4 24 | $-3.0M | $23.7M | ||
| Q3 24 | $4.0M | $82.9M | ||
| Q2 24 | $-151.0M | $-96.9M | ||
| Q1 24 | $-167.0M | $3.8M |
毛利率BLCOCOTY
| Q4 25 | — | 63.8% | ||
| Q3 25 | — | 64.5% | ||
| Q2 25 | — | 62.3% | ||
| Q1 25 | — | 64.1% | ||
| Q4 24 | — | 66.7% | ||
| Q3 24 | — | 65.5% | ||
| Q2 24 | — | 64.2% | ||
| Q1 24 | — | 64.8% |
营业利润率BLCOCOTY
| Q4 25 | 8.0% | 8.8% | ||
| Q3 25 | 7.4% | 11.7% | ||
| Q2 25 | -0.9% | 1.2% | ||
| Q1 25 | -7.3% | -21.6% | ||
| Q4 24 | 6.8% | 16.1% | ||
| Q3 24 | 3.6% | 14.2% | ||
| Q2 24 | 2.1% | 2.5% | ||
| Q1 24 | 0.5% | 5.6% |
净利率BLCOCOTY
| Q4 25 | -4.1% | -7.4% | ||
| Q3 25 | -2.2% | 4.3% | ||
| Q2 25 | -4.9% | -5.5% | ||
| Q1 25 | -18.6% | -31.2% | ||
| Q4 24 | -0.2% | 1.4% | ||
| Q3 24 | 0.3% | 5.0% | ||
| Q2 24 | -12.4% | -7.1% | ||
| Q1 24 | -15.2% | 0.3% |
每股收益（稀释后）BLCOCOTY
| Q4 25 | $-0.16 | $-0.14 | ||
| Q3 25 | $-0.08 | $0.07 | ||
| Q2 25 | $-0.18 | $-0.08 | ||
| Q1 25 | $-0.60 | $-0.47 | ||
| Q4 24 | $-0.00 | $0.02 | ||
| Q3 24 | $0.01 | $0.09 | ||
| Q2 24 | $-0.43 | $-0.11 | ||
| Q1 24 | $-0.48 | $0.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $383.0M | $436.7M |
| 总债务越低越好 | $5.0B | $3.0B |
| 股东权益账面价值 | $6.4B | $3.5B |
| 总资产 | $14.0B | $11.1B |
| 负债/权益比越低杠杆越低 | 0.78× | 0.85× |
8季度趋势，按日历期对齐
现金及短期投资BLCOCOTY
| Q4 25 | $383.0M | $436.7M | ||
| Q3 25 | $310.0M | $264.6M | ||
| Q2 25 | $266.0M | $257.1M | ||
| Q1 25 | $202.0M | $243.5M | ||
| Q4 24 | $305.0M | $249.6M | ||
| Q3 24 | $329.0M | $283.6M | ||
| Q2 24 | $285.0M | $300.8M | ||
| Q1 24 | $315.0M | $260.2M |
总债务BLCOCOTY
| Q4 25 | $5.0B | $3.0B | ||
| Q3 25 | $5.0B | $4.0B | ||
| Q2 25 | $5.0B | $4.0B | ||
| Q1 25 | $4.8B | $3.8B | ||
| Q4 24 | $4.8B | $3.4B | ||
| Q3 24 | $4.6B | $3.9B | ||
| Q2 24 | $4.6B | $3.8B | ||
| Q1 24 | $4.6B | $3.9B |
股东权益BLCOCOTY
| Q4 25 | $6.4B | $3.5B | ||
| Q3 25 | $6.4B | $3.6B | ||
| Q2 25 | $6.4B | $3.5B | ||
| Q1 25 | $6.4B | $3.5B | ||
| Q4 24 | $6.5B | $3.8B | ||
| Q3 24 | $6.6B | $4.0B | ||
| Q2 24 | $6.5B | $3.8B | ||
| Q1 24 | $6.7B | $4.0B |
总资产BLCOCOTY
| Q4 25 | $14.0B | $11.1B | ||
| Q3 25 | $13.8B | $12.1B | ||
| Q2 25 | $13.8B | $11.9B | ||
| Q1 25 | $13.4B | $11.5B | ||
| Q4 24 | $13.5B | $11.7B | ||
| Q3 24 | $13.5B | $12.5B | ||
| Q2 24 | $13.3B | $12.1B | ||
| Q1 24 | $13.3B | $12.3B |
负债/权益比BLCOCOTY
| Q4 25 | 0.78× | 0.85× | ||
| Q3 25 | 0.77× | 1.10× | ||
| Q2 25 | 0.77× | 1.12× | ||
| Q1 25 | 0.76× | 1.09× | ||
| Q4 24 | 0.74× | 0.89× | ||
| Q3 24 | 0.70× | 0.97× | ||
| Q2 24 | 0.71× | 1.00× | ||
| Q1 24 | 0.69× | 0.98× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $136.0M | $559.7M |
| 自由现金流经营现金流 - 资本支出 | $60.0M | $513.1M |
| 自由现金流率自由现金流/营收 | 4.3% | 30.6% |
| 资本支出强度资本支出/营收 | 5.4% | 2.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-66.0M | $390.8M |
8季度趋势，按日历期对齐
经营现金流BLCOCOTY
| Q4 25 | $136.0M | $559.7M | ||
| Q3 25 | $137.0M | $65.2M | ||
| Q2 25 | $35.0M | $83.2M | ||
| Q1 25 | $-25.0M | $-122.5M | ||
| Q4 24 | $22.0M | $464.5M | ||
| Q3 24 | $154.0M | $67.4M | ||
| Q2 24 | $15.0M | $176.5M | ||
| Q1 24 | $41.0M | $-170.0M |
自由现金流BLCOCOTY
| Q4 25 | $60.0M | $513.1M | ||
| Q3 25 | $63.0M | $11.2M | ||
| Q2 25 | $-54.0M | $34.9M | ||
| Q1 25 | $-135.0M | $-168.4M | ||
| Q4 24 | $-70.0M | $419.0M | ||
| Q3 24 | $94.0M | $-7.9M | ||
| Q2 24 | $-57.0M | $116.7M | ||
| Q1 24 | $-26.0M | $-234.3M |
自由现金流率BLCOCOTY
| Q4 25 | 4.3% | 30.6% | ||
| Q3 25 | 4.9% | 0.7% | ||
| Q2 25 | -4.2% | 2.8% | ||
| Q1 25 | -11.9% | -13.0% | ||
| Q4 24 | -5.5% | 25.1% | ||
| Q3 24 | 7.9% | -0.5% | ||
| Q2 24 | -4.7% | 8.6% | ||
| Q1 24 | -2.4% | -16.9% |
资本支出强度BLCOCOTY
| Q4 25 | 5.4% | 2.8% | ||
| Q3 25 | 5.8% | 3.4% | ||
| Q2 25 | 7.0% | 3.9% | ||
| Q1 25 | 9.7% | 3.5% | ||
| Q4 24 | 7.2% | 2.7% | ||
| Q3 24 | 5.0% | 4.5% | ||
| Q2 24 | 5.9% | 4.4% | ||
| Q1 24 | 6.1% | 4.6% |
现金转化率BLCOCOTY
| Q4 25 | — | — | ||
| Q3 25 | — | 0.96× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 19.60× | ||
| Q3 24 | 38.50× | 0.81× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -44.74× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
COTY
| Prestige | $1.1B | 68% |
| Consumer Beauty | $545.0M | 32% |
